TY  - JOUR
AU  - Wang, Haiyun
AU  - Nieto, Patricia
AU  - Zheng, Jie
AU  - Gómez-López, Gonzalo
AU  - Fernández-García, Fernando
AU  - Sanclemente, Manuel
AU  - Drosten, Matthias
AU  - Galán, Javier
AU  - Fajas, Lluis
AU  - Peng, Sheng-Bin
AU  - Santamaria, David
AU  - Musteanu, Mónica
AU  - Esteban-Burgos, Laura
AU  - Blanco-Aparicio, Carmen
AU  - Varela Bustos, Carmen
AU  - Guerra, Carmen
AU  - Caleiras, E
AU  - Martinez Torrecuadrada, Jorge Luis
AU  - Barbacid, Mariano
AU  - Caleiras, Eduardo
AU  - Martínez-Torrecuadrada, Jorge
PY  - 2020
DO  - 10.1073/pnas.2002520117
SN  - 0027-8424
UR  - http://hdl.handle.net/20.500.12105/14720
AB  - KRAS mutant lung adenocarcinomas remain intractable for targeted therapies. Genetic interrogation of KRAS downstream effectors, including the MAPK pathway and the interphase CDKs, identified CDK4 and RAF1 as the only targets whose genetic inactivation...
LA  - eng
PB  - National Academy of Sciences
KW  - Adenocarcinoma of Lung
KW  - Animals
KW  - Antineoplastic Agents
KW  - Cell Line, Tumor
KW  - Cyclin-Dependent Kinase 4
KW  - Disease Progression
KW  - Drug Resistance, Neoplasm
KW  - Gene Silencing
KW  - Humans
KW  - Lung Neoplasms
KW  - Mice
KW  - Mice, Inbred C57BL
KW  - Mutation
KW  - Proto-Oncogene Proteins c-raf
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Tumor Suppressor Protein p53
TI  - Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
TY  - journal article
ER  -